JPMorgan analyst Jeffrey Zekauskas upped his price target for Chemours to $55 citing his "sharply raised" earnings and EBITDA estimates following the company's Q2 results. The analyst keeps an Overweight rating on the shares.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here